Soligenix’s HyBryte featured in T-cell lymphoma study published in Europe

Soligenix announced that the results of its compatibility study evaluating HyBryte – synthetic hypericin – for the treatment of cutaneous T-cell lymphoma have been published in the Journal of the European Academy of Dermatology & Venereology Clinical Practice. The publication highlights the positive clinical results from study, HPN-CTCL-02, evaluating HyBryte in the treatment of CTCL. The treatment response results of 22% following 8 weeks of twice weekly HyBryte therapy reinforces and confirms the results of the Phase 3 FLASH trial published in the Journal of the American Medical Association Dermatology, despite the fact that patients in Study HPN-CTCL-02 were specifically selected to have more extensive disease consistent with its potential commercial use. All patients had improvements in their cumulative mCAILS score: average improvement of 36.4%. 7 of the 27 index lesions had at least a 50% improvement in their mCAILS score and 4 of the 27 index lesions were completely resolved after as little as 8 weeks of treatment.